Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...
The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.
“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...
PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.
In the 17th century, diagnosing diabetes meant tasting urine for sweetness – a crude yet pioneering method that laid the foundation for modern endocrinology. Today, medical science has evolved to ...
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P.
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
SAN FRANCISCO, CALIFORNIA / ACCESSWIRE / 14, 2025 / Nucs AI, a leader in AI-driven radiology solutions, is proud to announce that it has been awarded t ...
Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback